Avidity Biosciences Inc (RNA)
29.51
+0.79
(+2.75%)
USD |
NASDAQ |
May 17, 16:00
29.30
-0.21
(-0.71%)
After-Hours: 20:00
Avidity Biosciences Cash from Investing (Quarterly): -32.75M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -32.75M |
December 31, 2023 | 51.04M |
September 30, 2023 | -31.48M |
June 30, 2023 | 46.05M |
March 31, 2023 | -195.68M |
December 31, 2022 | -7.768M |
September 30, 2022 | 10.93M |
June 30, 2022 | -17.64M |
March 31, 2022 | -175.48M |
December 31, 2021 | -84.06M |
September 30, 2021 | -0.80M |
Date | Value |
---|---|
June 30, 2021 | 2.872M |
March 31, 2021 | -0.525M |
December 31, 2020 | -6.93M |
September 30, 2020 | -0.845M |
June 30, 2020 | 0.00 |
March 31, 2020 | -0.01M |
December 31, 2019 | -0.091M |
September 30, 2019 | -0.014M |
June 30, 2019 | -0.13M |
March 31, 2019 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-195.68M
Minimum
Mar 2023
51.04M
Maximum
Dec 2023
-22.17M
Average
-0.6625M
Median
Cash from Investing (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | -0.199M |
Vertex Pharmaceuticals Inc | -2.136B |
Codexis Inc | -28.56M |
Sarepta Therapeutics Inc | 218.80M |
PTC Therapeutics Inc | -114.93M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -70.38M |
Cash from Financing (Quarterly) | 389.44M |
Free Cash Flow | -143.80M |
Free Cash Flow Per Share (Quarterly) | -0.8175 |
Free Cash Flow to Equity (Quarterly) | -71.30M |
Free Cash Flow Yield | -6.31% |